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Aims: Tuberculosis (TB) infection of bones and joints accounts for 6.7% of TB cases in 
England and is associated with significant morbidity and disability. Public Health England 
reports that TB patients experience delays in diagnosis and treatment. This study’s 
objectives were to determine the demographics, presentation and investigation of bone 
and joint TB infections, to assist doctors assessing potential cases and identify avoidable 
delays.  
Patients and Methods: Retrospective observational study of all adults with positive TB 
cultures on specimens taken at a tertiary orthopaedic centre over two years. A 
laboratory information system search identified subjects. Demographics, clinical 
presentation, radiology, histopathology and key clinical dates were obtained from 
medical records. 
Results: Thirty-one adults were TB culture-positive: median age 37 years; 68% male; 
90% were migrants. Main sites affected were joints (32%), the spine (26%) and long 
bones (19%); 26% had multifocal disease. The most common presenting symptoms were 
pain (94%) and swelling (93%); “typical” TB symptoms, such as fever, sweats and weight 
loss were uncommon. Patients waited 7 months between symptom-onset and referral 
to the tertiary centre and 68 days from referral to starting treatment. Radiology 
suggested TB in 84%, but in 19% of these initial biopsy specimens were not sent for 
mycobacterial culture, necessitating a second biopsy. Rapid PCR-based testing for TB 
using Xpert MTB/RIF® was performed in 5 subjects; 80% tested positive for TB. These 
patients had reduced time from their diagnostic biopsy to starting treatment than those 
whose samples were not tested (8 days versus 36 days, p=0.016).  
Conclusion: Patients with bone and joint TB experience delays in diagnosis and 
treatment, some of which are avoidable. Maintaining a high index-of-clinical-suspicion 
and sending specimens for mycobacterial culture are crucial to avoid missing cases.  
Rapid diagnostic tests reduce delays-to-treatment and should be performed on patients 






Since 2011, there has been a year-on-year decline in the incidence of tuberculosis (TB)  
in England, with the number of cases falling from a peak of 15.6 per 100,000 (8,280 
cases) in 2011, to 10.5 per 100,000 (5,758 cases) in 2015. The proportion of extra-
pulmonary TB cases has remained constant (46.6% in 2015), and is higher in those born 
outside of the UK (53.1% of total TB cases) compared to those who are UK-born (30.1%). 
Bone and joint TB (BJTB), which includes spinal TB, accounts for 6.7% of England’s total 
TB cases and 14.4% of its extra-pulmonary cases1 . BJTB is associated with significant 
morbidity including chronic pain, deformity and disability2 so early diagnosis and 
treatment is desirable. 
 
Delays of weeks before starting TB treatment is common for patients: in England, 28% 
of patients with pulmonary TB experience delays of four months or longer between 
symptom-onset and starting treatment1. European studies of spinal TB also report 
diagnostic delays3-5. With just 386 cases of BJTB notified in 20151, it is a condition rarely 
seen by surgical teams, particularly in non-specialist centres outside London. 
Inexperience with its clinical presentation and diagnostic work-up and its varied 
presentation at different anatomical sites risks these patients experiencing long delays 
before starting treatment, which risks clinical deterioration and worsening disability6. 
 
We performed this retrospective observational study of BJTB aiming to describe the 
typical demographics, presentation and investigation of these patients, to assist doctors 
assessing potential cases. We investigated the clinical pathways through which diagnosis 
was confirmed and treatment started, aiming to identify avoidable delays whose 
prevention might reduce time-to-treatment.  
 
Patients and Methods 
 
We conducted this study at a large specialist orthopaedic hospital in the UK which 
includes a regional Sarcoma Unit, accepting regional referrals for patients with possible 
sarcoma. Bone and joint samples were cultured for TB using the BACTEC MIGIT system 
(BD, Franklin Lakes, New Jersey, USA). Suspected mycobacterial isolates were sent to 
Public Health England’s (PHE) Mycobacterial reference lab for confirmation, speciation 
and sensitivity-testing. Rapid Polymerase Chain Reaction (PCR)-based testing was 
performed locally using the Xpert MTB/RIF® (Cepheid, Sunnyvale, California, USA) assay. 
 
We included all patients aged 18 years and over who had pathological specimens taken 
at the centre between 1st June 2012 and 30th May 2014 which grew Mycobacterium 
tuberculosis (Mtb). Subjects were identified via a laboratory information search system 
(WinPath). Paper and electronic records were accessed with appropriate permissions. A 
standardised proforma recorded: demographics, clinical presentation, radiological 
findings, histopathology and important dates (including first presentation, referral to the 
specialist orthopaedic centre, biopsy, results, communication of results to the GP and/or 
referring hospital, referral to TB services, commencement of anti-tuberculous 
antimicrobials). Data were anonymised and recorded in Excel (2010).  
 
Analysis 
Data were analysed using Microsoft Excel 2010 and GraphPad 2017 (GraphPad 
Software, Inc. California, USA). After descriptive study of the different variables, Mann-
Whitney U test was applied for comparison of medians. Tests were two-tailed; a P-value 




During the study period, cultures from 31 adult patients were positive for TB. All were 
drug-susceptible, meaning sensitive to first-line antibiotics (Rifampicin, Isoniazid, 
Pyrazinamide and Ethambutol).  
 
Demographic characteristics 
Subjects’ median age was 37 years (IQR 29-53 years); 68% were male (n=31). Ninety 
percent (n=28) were born outside the UK, predominantly in southern Asia (Table 1), 
living in the UK for a median of 6 years at the time of diagnosis (IQR 3.5-14 years, n=25). 
Three subjects were UK-born; their median age was 41, range 29 to 85 years; their self-
reported ethnicities were “White British”, “Pakistani “and “Black-other”. No patients 
were known to have Human Immunodeficiency Virus (HIV) prior to diagnosis. One 
patient was tested for HIV at the orthopaedic centre and tested negative. 
 
Site of infection and clinical features 
The most commonly affected sites were joints (32%, n=31) and the spine (26%), 
followed by long bones (19%) and axial bones (13%). Multifocal disease, defined as 
more than one anatomical site (bones, joints or elsewhere),was present in 26%; 6 of 
these 8 cases had spinal involvement (Table 2). Commonly reported symptoms were 
pain (94%, 29/31) and swelling (93%, 26/28) but “typical” TB symptoms were 
uncommon, with 21% (3/14) reporting fever, 14% (2/14) night sweats and 56% (9/16) 
weight loss. Few were asked about TB contacts (7/31) or past infection (1/22 patients). 
Where this information was available, three reported a TB contact and one reported a 
prior history of TB. 
 
Treatment delays and Referral pathways 
Median time from symptom-onset to starting anti-tuberculous therapy was 9 months 
(IQR 6-20 months, n=26) with 37% waiting one year or longer. We examined the 
referral, diagnostic and treatment processes in further detail, to identify potentially 
avoidable areas of delay in the patients’ pathway between symptom-onset and starting 
treatment. 
 
Median time from symptom-onset to referral to the tertiary centre was 7 months (IQR 
3-13.5 months, n=21). There was insufficient data to establish what proportion of this 
time was attributable to the patient not seeking medical advice, and what proportion 
was spent being managed in primary or local secondary care. Ninety percent (28/31) 
were referred to the tertiary centre via the sarcoma pathway and all of these were seen 
within the two-week target for suspected cancer referrals. Referral data were available 
for two of the three non-sarcoma referrals; they were seen in clinic 27 and 33 days after 
referral. Median time between referral to the specialist centre and starting TB 
treatment was 68 days (IQR 47-103 days, n=30); 33% waited 3 months or longer; 10% 
waited 6 months or longer.  
 
After clinical review, 97% of patients underwent Magnetic resonance imaging (MRI). It 
was contraindicated in one patient who had a CT scan. In 84% of cases, the radiologist 
reported TB in their differential diagnosis based on the imaging, prior to biopsy (n=31). 
All patients underwent a biopsy: 92% had specimens sent for histopathology and 77% 
for TB culture (n=31).  Seven patients’ samples from their first biopsy (23%) were not 
sent for TB culture; TB was suspected in five of these; all seven required a second 
biopsy. Median time to the second biopsy was 39 days (IQR 19-52 days, n=7). 
 
Pathology results 
 Granulomas were seen in 87% (20/23) of histopathology samples; no acid-fast bacilli 
(AFB) were seen (n=25). TB cultures were positive in 92% (22/24) of first biopsies; 
median time to culture positivity was 22 days (IQR 16-38 days, n=31); plus 10 days (IQR 
9-16 days, n=31) for confirmation of Mtb species Xpert MTB/RIF®  was performed on 
five patients’ samples, taking two days from biopsy to results (IQR 2-7 days, n=5); four 
tested positive for Mtb and negative for rifampicin-resistance. One patient started anti-
tuberculous treatment before their biopsy; for the remaining 30 patients, those whose 
samples were tested with Xpert MTB/RIF® waited significantly less time from their 
diagnostic biopsy to starting treatment than those whose samples were not tested 
(median 8 days with Xpert MTB/RIF®, n=5, versus 36 days without, n=25, p=0.016). 
 
Starting treatment 
Anti-tuberculous treatment was started in 13 patients prior to TB cultures becoming 
positive. For the remaining 18, median time from culture-positivity to treatment was 20 
days (IQR 9-33 days, n=18). Of these 18, 10 were referred onwards prior to culture-
positivity (to TB clinic (5), the GP (4), referring hospital (1)). Referral-to-treatment time 
was available for 4/6 who were referred after cultures grew TB: median time was four 
days for the three referred directly to TB clinic; one patient was referred to the GP and 




Diagnosing BJTB is challenging and there is no specific national guidance on the optimal 
diagnostic pathway. In this study of culture-positive BJTB, patients waited an average of 
9 months between symptom-onset and starting anti-tuberculous therapy, substantially 
longer than the national average time for pulmonary cases of 74 days1 and longer than 
reported in previous European studies on spinal TB.3-5. Seven of these months occurred 
prior to referral to the specialist centre. We could not determine what proportion of this 
time was attributable to delays in patients engaging with medical care, and what was 
attributable to patients being managed within primary and secondary care, but the non-
specific clinical presentation of BJTB is likely to have been a contributing factor. Omitting 
to send biopsy specimens for TB culture contributed a further 5 weeks to delays; waiting 
for TB culture results took 3 to 4 weeks; not referring directly to TB clinic may have also 
contributed to delays. Maintaining a high index-of-clinical-suspicion, targeted use of 
rapid molecular tests and direct patient referral to TB services should reduce time-to-
treatment in these patients.  
 
Clinical presentation 
In this BJTB cohort, patients were typically young male migrants from southern Asia. 
This is in keeping with national data from PHE: 73% of patients diagnosed with TB in 
2015 were born outside of the UK, most commonly India, Pakistan and Bangladesh1 . 
Previous studies on BJTB in low-endemic countries report varying proportions of cases 
occurring in immigrants, with some centres reporting high proportions (92% UK3; 83% 
Denmark7, 66% Netherlands8) and others in France9 and Spain5 reporting much lower 
figures. Countries-of-origin of affected immigrants vary in these studies, likely reflecting 
differing migration trends.  
 
Few patients presented with “typical” TB symptoms of fevers and night sweats and just 
over half reported weight loss. INon-specific symptoms of pain and swelling were very 
common,consistent with previous studies3,5,7, meaning  clinicians cannot rely on clinical 
presentation alone to suggest underlying TB. Maintaining a high index-of-suspicion and 
knowledge of local epidemiology and high-risk groups are essential to ensure the 
necessary microbiological tests are requested and the diagnosis is not missed. 
 
The spine is usually the most common site of BJTB (65% in PHE national data1, 54.3% in 
a Danish cohort7) but just 26% of our cohort had spinal involvement. This distribution 
likely reflects the fact that 90% of our patients were referred via the sarcoma pathway 
and the centre does not take emergency admissions. Clinically, TB can mimic sarcoma: 
both diseases can be insidious, affect younger adults and present with swelling and 
pain10. European studies have reported up to 35% of BJTB patients as having 
concomitant pulmonary TB3,7,9.  While 26%of our cohort had multifocal disease,none 
had pulmonary involvement.Acutely unwell patients with pulmonary involvement would 





In the majority of cases, radiological and histopathological findings suggested underlying 
TB. MRI was very useful, with TB considered in 83% of MRI reports. Data showing what 
proportion of radiology reports overall list TB in the differential diagnosis were 
unavailable. Radiological features of BJTB are diverse and non-specific. In the spine, TB 
usually affects multiple anterior vertebral bodiesand adjacent discs; paraspinal 
abscesses are common. Vertebral collapse and anterior wedging are seen in advanced 
infection. TB infection of the bone causes a chronic osteomyelitis, so radiological 
features are non-specific. Similarly tuberculous arthritis resembles other infectious and 
inflammatory arthritides2,11. 
 
Typical histopathological features of TB include granulomas and AFB12-13. Granulomas 
were seen frequently in this study: their presence provides strong evidence for 
underlying TB, useful when TB cultures are negative. Conversely, AFB were not seen in 
any of our cases. Visible only when mycobacterial burden is high and affected by 
formalin14, their absence should not deter the clinician from diagnosing TB.   
 
Every patient in this study underwent a biopsy but 23% did not have samples sent for 
mycobacterial culture, despite TB being in the differential diagnosis for most of them.  
All seven had to undergo a second biopsy and waited an average of five weeks for the 
procedure. Biopsy is crucial for confirming a diagnosis of TB. All efforts should be made 
to obtain tissue specimens and send them to histopathology and microbiology. 
Microbiological specimens must be sent formalin-free15, as formalin sterilises any 
organisms present, rendering cultures falsely negative. National Standards for 
Microbiology recommend that routine mycobacterial culture is considered for all non-
postoperative spinal infections16. We recommend that mycobacterial culture is 
requested for any patient in whom infection or malignancy is suspected, or where there 
is clinical uncertainty. This recommendation has been implemented in local policy since 
the study period.  
 
Mycobacterial culture is essential for obtaining drug-susceptibility information and is 
another important reason for performing a biopsy whenever possible. While no patients 
in this study had drug-resistant strains, 7.4% of England’s TB cases are resistant to at 
least one first-line antibiotic and 1.3% are “Multi-drug resistant” (MDR), meaning the 
isolate is resistant to both isoniazid and rifampicin1. Worldwide, 5% of TB cases are 
MDR, with rates over 20% in some ex-Soviet states17. In England, most MDR-TB cases 
are imported from Latvia (20%) and Lithuania (23.9%)1.  
 
Rapid Molecular Tests  
While mycobacterial culture remains the gold standard for diagnosing tuberculosis18, its 
primary disadvantage is the time it takes to grow TB: median time to culture positivity in 
this study was 22 days. Five patients’ samples were tested with Xpert® MTB/RIF; 80% 
returned a positive result, with an average turn-around time of two days and those 
whose samples were tested with Xpert® MTB/RIF waited four weeks less from their 
diagnostic biopsy to starting treatment than those whose samples were not tested. 
 
Xpert® MTB/RIF is a PCR-based assay that allows the rapid diagnosis of TB within just a 
few hours. It was initially developed for use with sputum to diagnose pulmonary TB, 
where its sensitivity approaches 100% for smear-positive disease19. The World Health 
Organisation (WHO) recommends Xpert® MTB/RIF for testing non-respiratory samples 
in patients suspected of having extra-pulmonary TB20. Its sensitivity in tissue ranges 
from 77% to 90% (specificity 96-98%) when compared to mycobacterial culture, with 
the highest sensitivities in lymph node samples. In pus, sensitivities range from 77% to 
96% (specificity 46%-86%); lower sensitivities are reported with fluid samples (sensitivity 
50-76%)21-23. In BJTB studies, sensitivities of 96% (spinal TB, South Africa)24 and 100% 
(BJTB, China)25 have been reported. Xpert® MTB/RIF also rapidly detects rifampicin-
resistance with a sensitivity approaching 100%19, making it an invaluable tool when 
investigating patients from high-risk countries for MDR-TB.   
 
GenoType MTBDRplus® (Hain Lifescience GmbH, Nehren, Germany) is another 
molecular test which can provide rapid confirmation of the presence of Mtb DNA, and 
common mutations associated with rifampicin- and isoniazid-resistance. Results are 
typically available within two to three days and reported sensitivities in pulmonary 
samples are comparable to Xpert® MTB/RIF26. GenoType MTBDRplus® was assessed in 
the Chinese BJTB study and found to have a sensitivity of 87.5% for culture-confirmed 
cases and 63.6% for culture-negative “probable” cases25.   
 
Almost all hospitals have access to Xpert® MTB/RIF and GenoType MTBDRplus®, though 
most microbiology departments do not offer it “in-house”27. The positive predictive 
value of the test is affected by the prevalence of TB. Therefore, in low prevalence 
countries such as the UK, they should not be used indiscriminately due to the risk of 
false-positive results. Where clinical suspicion and therefore pre-test probability is high, 
their use can reduce time-to-diagnosis and treatment from weeks to days. Requesting 
doctors should be aware of the possibility of false-negatives and should not be deterred  
by a negative PCR in a high-risk patient.  We recommend considering rapid molecular 
testing for samples from all patients where BJTB and sarcoma are in the differential 
diagnosis and are changing local policy to reflect this. Given the importance of targeted 
testing with these assays and their interpretation, we recommend involving an Infection 
specialist early. 
 
Initiating anti-tuberculous treatment and referral to TB services 
Over 40% of patients in this study started TB treatment before positive culture results 
were available. Where the patient is very symptomatic and the index-of-suspicion is 
high, this is a reasonable approach that should be made in partnership with a TB 
specialist. However, unless there is a clinical indication to start treatment urgently, 
antibiotics should not be initiated until after a biopsy has been performed and samples 
sent for mycobacterial culture. This will maximise the likelihood of growing TB from the 
tissue sample, which will enable confirmation of the diagnosis and drug-susceptibility 
testing. 
 
The patient’s local TB clinic is responsible for overseeing their anti-tuberculous 
treatment, which in most cases will be a 6-month course18, and initiating contact 
tracing. In this study, there was variation in how and when patients were referred to TB 
services. Numbers are too small to make a meaningful comparison, but where the TB 
diagnosis is confirmed, we recommend referring patients directly to their local TB 
service to avoid unnecessary delays.  
 
Limitations 
This study was conducted in a tertiary centre which receives UK-wide referrals, so it 
manages more BJTB cases than most. Its role as a sarcoma centre likely distorts its case-
mix as seen with the under-representation of spinal TB, but many of our findings and 
recommendations will be applicable to general orthopaedic units.  
 
In this study, most patients had been symptomatic for months before referral to the 
tertiary centre. Unfortunately there was insufficient data to establish what proportion 
of this time was attributable to the patient not seeking medical advice and what was 
attributable to time being managed in primary or local secondary care. If the latter were 
a significant contributing factor, additional training of general practitioners and hospital 
doctors might be beneficial. There was insufficient information in medical records to 
establish why some patients with suspected BJTB were not started on treatment until 
after culture results were available. 
Mycobacterial culture is not 100% sensitive13: nationally 45.9% of extra-pulmonary TB 
cases are culture-confirmed (compared to 72.7% of pulmonary cases)1. Our study 
includes only patients with culture-positive BJTB and therefore misses those treated 
presumptively for BJTB without positive cultures. Many patients at our centre are 
referred to and from other hospitals and their ultimate diagnosis is not always available 
locally. As we could not reliably capture this group, they were not included in this study.  
 
As with any retrospective study, some data are incomplete despite our best efforts. We 
are confident that our Winpath system search captured all cases of culture-positive BJTB 
diagnosed during the study period.  
 
Conclusions 
Patients with BJTB typically wait months for diagnosis and treatment and some of these 
delays are avoidable. BJTB’s non-specific presentation means that an index-of-suspicion 
must be maintained to avoid missing cases, particularly in high-risk patients (young, 
male, recent migrants) with bone and joint lesions. Mycobacterial culture of biopsy 
specimens is crucial for diagnosis and drug-susceptibility testing and should be 
performed in any case where infection or malignancy is being considered or when there 
is clinical uncertainty. Early involvement of an Infection Specialist is recommended: they 
can advise on and expedite microbiological testing and access specialist diagnostic tests 
such as Xpert® MTB/RIF. The use of rapid diagnostic tests such as Xpert® significantly 
speeds up diagnosis and starting anti-tuberculous therapy. They can also advise on 
antibiotic treatment and facilitate engagement with local TB services. On diagnosis, the 
managing team should refer the patient directly to their local TB service.  
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India 5 3 3 
Pakistan 1 1 4 
UK 0 3 0 
Afghanistan 0 1 1 
Bangladesh 1 1 0 
Fillipines 0 1 0 
Malaysia 0 1 0 
Nepal 1 0 0 
Somalia 0 0 1 
Sri Lanka 0 0 1 
Not 
documented 
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  Hip 0 1 1 
  Knee 2 1 0 
  Ankle 0 0 1 
  Shoulder 0 1 0 
  Elbow 1 1 1 





  Foot/ toe 0 2 1 
  Hand/ finger 0 2 0 
  Arm 0 0 0 





  Spine  1 0 1 
  Sacrum 0  0 1 
  Sternum 1 0 0 
MULTIFOCAL 
 
    








    
  Soft tissue 1 1 1 
 
 
 
 
